Adjustment

Quarterhill Announces Closing of Red Fox Acquisition

Retrieved on: 
Monday, April 8, 2024
Intelligent transportation system, Classification, Red, Acquisition, Software, Quantum, Adjustment, TSX, Lidar, Red fox

TORONTO, April 8, 2024 /PRNewswire/ - Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), a leading provider of tolling and enforcement solutions in the Intelligent Transportation System ("ITS") industry, announces that it has completed the previously announced acquisition of Red Fox I.D.

Key Points: 
  • TORONTO, April 8, 2024 /PRNewswire/ - Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), a leading provider of tolling and enforcement solutions in the Intelligent Transportation System ("ITS") industry, announces that it has completed the previously announced acquisition of Red Fox I.D.
  • Limited ("Red Fox").
  • Based in Haddenham, England, Red Fox is a profitable and growing provider of Automatic Vehicle Detection and Classification ("AVDC") software to the tolling industry.
  • "The Red Fox transaction met both our strategic and financial criteria for an acquisition, and we are pleased to welcome their team to Quarterhill," said Chuck Myers, CEO of Quarterhill.

Maxeon Solar Technologies Announces Preliminary Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Monday, April 8, 2024
Tax, Forecasting, Acquisition, Nature, Loss, Adjustment, Note, Depreciation, GAAP, IBC, Insurance

Non-GAAP operating expenses is defined as operating expenses excluding stock-based compensation and restructuring charges and fees.

Key Points: 
  • Non-GAAP operating expenses is defined as operating expenses excluding stock-based compensation and restructuring charges and fees.
  • We also use these non-GAAP measures internally to assess our business, financial performance and current and historical results, as well as for strategic decision-making and forecasting future results.
  • Given our use of non-GAAP measures, we believe that these measures may be important to investors in understanding our operating results as seen through the eyes of management.
  • This is excluded from our Adjusted EBITDA financial measure as it is non-recurring and not reflective of ongoing operating results.

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Monday, March 25, 2024
Tax, Growth, Tufts University, Patient, Extracellular matrix, Classification, Sale, Acquisition, Nature, Adjustment, SMTI, Infection, Depreciation, GAAP, Peptide

Zach Fleming, Sanara's CEO, stated, “During 2023, the Sanara team achieved several key strategic and operational milestones that position the Company for continued strong growth in 2024.

Key Points: 
  • Zach Fleming, Sanara's CEO, stated, “During 2023, the Sanara team achieved several key strategic and operational milestones that position the Company for continued strong growth in 2024.
  • The Company’s products were contracted or approved to be sold in more than 3,000 hospitals/ambulatory surgery centers as of December 31, 2023.
  • In October 2023, Sanara recorded its first sale of ALLOCYTE® Plus, a human cell and tissue-based product.
  • In November 2023, Sanara announced the publication of a retrospective study involving 5,335 patients.

AGILON HEALTH, INC. (NYSE: AGL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against agilon health, inc.

Retrieved on: 
Monday, March 25, 2024
Health, District court, Patient, SPO, News, LLP, Complaint, Adjustment, Action Replay, Court, Advertising, IBNR, Security (finance)

Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .

Key Points: 
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • If you wish to serve as lead plaintiff, you must move the Court no later than May 20, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Algoma Steel Provides Fiscal Fourth Quarter 2024 Guidance

Retrieved on: 
Monday, March 25, 2024
STE, Adjustment, TSX, Electric arc furnace, ASTL, EAF, Coal

MARIE, Ontario, March 25, 2024 (GLOBE NEWSWIRE) -- Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma” or “the Company”), a leading Canadian producer of hot and cold rolled steel sheet and plate products, today provided guidance for its fiscal fourth quarter ending March 31, 2024.

Key Points: 
  • MARIE, Ontario, March 25, 2024 (GLOBE NEWSWIRE) -- Algoma Steel Group Inc. (NASDAQ: ASTL; TSX: ASTL) (“Algoma” or “the Company”), a leading Canadian producer of hot and cold rolled steel sheet and plate products, today provided guidance for its fiscal fourth quarter ending March 31, 2024.
  • Fiscal 2024 fourth quarter total steel shipments are expected to be in the range of 445,000 to 460,000 tons and Adjusted EBITDA is expected to be in the range of $30 million to $40 million.
  • As previously announced, during the quarter Algoma experienced an unplanned outage at its blast furnace in connection with a utility corridor collapse at its coke-making facility.
  • It is expected that the resultant outage reduced production by 120,000 to 150,000 net tons, significantly impacting Adjusted EBITDA performance in the quarter.

Bitcoin Depot Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 25, 2024
Fastlane, Growth, FY, Partnership, Webcast, Sale, BTM, Bitcoin ATM, Software, Adjustment, GSR, Cryptocurrency

Gross Profit in the fourth quarter of 2023 was $17.9 million, up 23% from $14.6 million for the fourth quarter of 2022.

Key Points: 
  • Gross Profit in the fourth quarter of 2023 was $17.9 million, up 23% from $14.6 million for the fourth quarter of 2022.
  • Gross Profit margin in the fourth quarter of 2023 was 12.1% compared to 9.8% in the fourth quarter of 2022.
  • Total operating expenses were $17.0 million for the fourth quarter of 2023, compared to $14.8 million for the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was $1.5 million, compared to a net loss of $0.5 million for the fourth quarter of 2022.

Digerati Technologies Reports Revenue of $7.56 Million for Second Quarter Fiscal Year 2024

Retrieved on: 
Monday, March 25, 2024
Administration, Tax, Conference, Three Months, CFO, EPS, SAN, Support, Nature, Loss, Adjustment, Depreciation, GAAP, Net, Unified communications, OTCQB

SAN ANTONIO, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Digerati Technologies, Inc. (OTCQB: DTGI) ("Digerati" or the "Company"), a provider of cloud services specializing in Unified Communications as a Service (“UCaas") solutions for the small to medium-sized business (“SMB”) market, announced today financial results for the three and six months ended January 31, 2024, the Company’s second quarter for its Fiscal Year 2024.

Key Points: 
  • Key Financial Highlights for the Three Months Ended January 31, 2024 (Compared to Three Months Ended January 31, 2023)
    Revenue decreased 5% to $7.565 million compared to $7.941 million.
  • Net loss attributable to Digerati’s common shareholders was $3.556 million, compared to net income attributable to Digerati’s common shareholders of $0.220 million.
  • Six Months ended January 31, 2024, Compared to Six Months ended January 31, 2023
    Revenue for the six months ended January 31, 2024, was $15.219 million, a decrease of $0.852 million, or 5%, compared to $16.071 million for the six months ended January 31, 2023.
  • Operating loss for the six months ended January 31, 2024, was $2.446 million, an increase of $0.481 million or 24%, compared to $1.965 million for the six months ended January 31, 2023.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against agilon health, inc. - AGL

Retrieved on: 
Saturday, March 23, 2024
Prior, News, Ext, LLP, Complaint, Adjustment, Pomerantz, Action Replay, Court, Pharmaceutical industry

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL).

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against agilon health, inc. (“agilon” or the “Company”) (NYSE: AGL).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • The class action concerns whether agilon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

CC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that The Chemours Company Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Friday, March 22, 2024
Annual report, Ethics, CC, CFO, Air conditioning, Electronics, Refrigeration, Controller, Transport, Senior, Complaint, Adjustment, Plastic, Collection, Court, Audit committee, Person, Audit

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) and certain of its officers.

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against The Chemours Company (“Chemours” or “the Company”) (NYSE: CC) and certain of its officers.
  • Prior to and during the Class Period, according to the Complaint, Chemours set and publicized certain criteria for executive compensation.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Theratechnologies Announces Update on its Preclinical Oncology Research Program

Retrieved on: 
Friday, March 22, 2024
Patient, Cancer, Adjustment, AACR, TSX, PDC

MONTREAL, March 22, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will phase down its preclinical oncology research activities. The Company will continue to prioritize its ongoing Phase 1 clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer. All figures below are in U.S. dollars.

Key Points: 
  • MONTREAL, March 22, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will phase down its preclinical oncology research activities.
  • The Company will continue to prioritize its ongoing Phase 1 clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
  • “I am very proud of our exceptional research team, whose work has contributed greatly to the scientific discourse and understanding of advanced cancers,” said Paul Lévesque, President and CEO at Theratechnologies.
  • “Our investment in the SORT1+ Technology™ platform over the past five years has generated important evidence on multiple peptide-drug conjugates with different payloads.